but the HTN market didn't reach that point after the first pretty effective drug was approved. Once you had multiple drugs in multiple classes even then there was innovation - ARBs aren't any more effective than ACE inhibitors, but they became mega blockbusters simply because of the adverse event profile (ARB = no risk of cough basically) so my point is that unless VKTX has a perfect drug, there is going to be room to innovate and still reap huge rewards given the massive size of the market Maybe VKTX will look at a FDC w a FXR agonist? HIV is another good example where you can go from *very* good to even better - both on efficacy w Integrase inhibitors and safety w TDF vs TAF
News 
Market Data 
Discover 
